Taro Pharmaceuticals Inc., Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Taro Pharmaceuticals Inc., Pharmaceutical Import Records from India — 12 Products, $6.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Taro Pharmaceuticals Inc., — Pharmaceutical Importer Profile (2026) | 12 Products, $6.8M Trade | TransData Nexus

Taro Pharmaceuticals Inc.,

Pharmaceutical Importer · Canada · Advanced Oncology Focus · $6.8M Total Trade · DGFT Verified

Taro Pharmaceuticals Inc., is a pharmaceutical importer based in Canada with a total trade value of $6.8M across 12 products in 6 therapeutic categories. Based on 137 verified import shipments from Indian Customs (DGFT) records, Taro Pharmaceuticals Inc., is the #1 buyer in 4 products including Sunitinib, Dasatinib, Doxorubicin. Taro Pharmaceuticals Inc., sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

Taro Pharmaceuticals Inc., — Import Portfolio & Supplier Network

Taro Pharmaceuticals Inc., import network — 12 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Taro Pharmaceuticals Inc.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$7.3M	189	100.0%

Taro Pharmaceuticals Inc., sources from 1 verified Indian supplier across 146 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Testosterone gel 1% w/w, 5.0 GM	$150.0K	3
Taro-testosterone cypionate injection	$150.0K	3
Taro-tramadol hydrochloride extended	$150.0K	3
Taro-testosterone cypionate injection 1000MG/10ML(100MG/ML, 10ML/vial) Pack : 1vial (319 shippers on 12 pallets)	$150.0K	3
Ciprofloxacin (0.3%) and dexamethasone (0.1%) sterile otic suspension USP (for canada)	$150.0K	3
Taro-temozolomide 20MG capsules [8050 Pack x 1x5] batch no. haf0556a mfg. dt. 03/2024 exp. dt.	$150.0K	3
Taro-temozolomide 100MG capsules [16414pack x 1x5] batch no. haf0558a & haf0559a mfg. dt. 02/2024 exp. dt.	$150.0K	3
Testosterone gel 1 % w/w, 5.0 GM (professed standard) (Pack: 13552 x 30) batch no. as per invoice.	$150.0K	3
Taro-temozolomide 140MG capsules [8307 Pack x 1x5] batch no. haf0730a & haf0731amfg dt: 03/2024 exp dt	$150.0K	3
Testosterone gel 1 % w/w, 5.0GM (professed standard) [13375 Pack x 30] (b no. haf0579a md. 03/2024 ed. 08/2025 &	$150.0K	3
Testosterone gel 1% w/w, 2.5 GM	$148.2K	3
Taro-temozolomide 5MG capsules [25247 Pack x 1x5] batch no. haf0382b mfg. dt. 02/2024 exp. dt.	$140.9K	3
Testosterone gel 1 % w/w, 2.5GM (professed standard) [7232 Pack x 30] (batch no.haf0818a, haf0819a & haf0820a mfg dt	$137.4K	3
Taro-testosterone 40MG capsules (testosterone undecanoate soft gelatin capsule 40MG professed standard)[7518	$117.9K	3
Taro-testosterone 40MG capsules Pack	$100.0K	2

Import Portfolio — Top 12 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Temozolomide	Advanced Oncology	$1.3M	26	2.6%	2
2	Sunitinib	Advanced Oncology	$900.0K	18	1.1%	1
3	Budesonide	Respiratory	$700.0K	14	0.4%	18
4	Dasatinib	Advanced Oncology	$600.0K	12	3.7%	1
5	Doxorubicin	Oncology	$600.0K	12	0.7%	1
6	Capecitabine	Advanced Oncology	$578.8K	13	0.7%	11
7	Dexamethasone	Corticosteroids	$450.0K	9	0.2%	15
8	Tofacitinib	Advanced Oncology	$450.0K	9	5.1%	1
9	Tramadol	Analgesics & Antipyretics	$450.0K	9	0.1%	12
10	Lenalidomide	Advanced Oncology	$400.0K	8	0.0%	15
11	Ras	Ayurvedic & Herbal Products	$250.0K	5	0.1%	16
12	Melphalan	Advanced Oncology	$100.0K	2	0.8%	11

Taro Pharmaceuticals Inc., imports 12 pharmaceutical products across 6 categories into Canada totaling $6.8M. The company is the #1 buyer for 4 products: Sunitinib, Dasatinib, Doxorubicin, Tofacitinib.

Taro Pharmaceuticals Inc., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Taro Pharmaceuticals Inc. is a Canadian subsidiary of Taro Pharmaceutical Industries Ltd., a global, research-driven specialty pharmaceutical company established in 1950. Headquartered in Brampton, Ontario, Taro Pharmaceuticals Inc. specializes in the development, manufacturing, and marketing of affordable prescription and over-the-counter medications. The company focuses on generic products, including topical dermatological treatments such as creams, ointments, and gels, as well as solid dosage forms like tablets and capsules. Taro's commitment to research and development has positioned it as a significant player in the specialty pharmaceutical sector. (taro.ca)

In June 2024, Taro Pharmaceutical Industries Ltd. became a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited, India's largest specialty generic pharmaceutical company. This acquisition has further strengthened Taro's global presence and resources, enhancing its ability to deliver high-quality pharmaceutical products to the Canadian market. (taro.ca)

2Distribution Network

Taro Pharmaceuticals Inc. operates a manufacturing facility in Brampton, Ontario, which serves as its primary distribution hub. The company distributes its products across Canada, supplying wholesalers, drugstore chains, mass merchandisers, healthcare institutions, and independent pharmacies. Taro's strategic location in Ontario facilitates efficient logistics and timely delivery to various regions within Canada. While the company primarily focuses on the Canadian market, its affiliation with Sun Pharmaceutical Industries Limited provides access to a broader international distribution network, potentially extending its reach beyond Canada. (taro.ca)

3Industry Role

Taro Pharmaceuticals Inc. functions as a primary wholesaler and distributor within Canada's pharmaceutical supply chain. By manufacturing and marketing a diverse range of generic and proprietary pharmaceutical products, the company plays a crucial role in ensuring the availability of affordable medications to Canadian consumers. Taro's emphasis on dermatology and niche markets differentiates it from competitors, allowing it to serve specialized therapeutic areas effectively. (taro.ca)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Taro Pharmaceuticals Inc.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Taro Pharmaceuticals Inc. imports finished pharmaceutical formulations exclusively from Sun Pharmaceutical Industries Limited, its parent company. Between 2022 and 2026, Taro imported products totaling $6.8 million USD across 137 shipments, with a portfolio concentration of 60.5% in the top five products. This single-source dependency indicates a strategic choice to maintain consistent quality and supply chain efficiency. The high volume of imports from a single supplier suggests a stable and reliable relationship, reducing the risks associated with supplier diversification. However, this concentration also means that any disruptions within Sun Pharma could significantly impact Taro's operations.

2Supply Chain Resilience

Taro Pharmaceuticals Inc.'s supply chain is closely integrated with Sun Pharmaceutical Industries Limited, which manufactures the majority of Taro's imported products. This vertical integration enhances supply chain resilience by ensuring consistent product quality and availability. The limited number of suppliers and formulations imported suggests a focused product strategy, potentially reducing complexity in supply chain management. However, the reliance on a single supplier for a significant portion of its product portfolio may expose Taro to risks if Sun Pharma faces operational challenges or regulatory issues.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada, which enforces the Food and Drugs Act and its regulations. These regulations govern the importation, sale, and distribution of pharmaceutical products to ensure they meet safety, efficacy, and quality standards. The marketing authorization pathway for Indian generics involves obtaining a Drug Identification Number (DIN) from Health Canada, which requires submission of comprehensive product information, including clinical data and manufacturing details. Additionally, the Canadian Generic Pharmaceutical Association (CGPA) provides guidelines and standards for generic drug manufacturers operating in Canada.

2Import Licensing & GMP

Import licensing in Canada is managed by Health Canada, which requires importers to hold a valid establishment license. This license ensures that the importer complies with Good Manufacturing Practices (GMP) and other regulatory requirements. Health Canada recognizes GMP certificates from reputable authorities, including the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Taro Pharmaceuticals Inc. must ensure their manufacturing facilities are certified by one of these recognized bodies to meet Canadian regulatory standards.

Taro Pharmaceuticals Inc., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Taro Pharmaceuticals Inc. focuses on therapeutic areas such as advanced oncology, respiratory, and oncology, with the top three categories accounting for 83.1% of its imports. This strategic focus aligns with market demand for specialized treatments in these areas. The company's emphasis on advanced oncology and oncology reflects a commitment to addressing complex and high-need medical conditions, while the inclusion of respiratory products indicates responsiveness to prevalent health concerns. By concentrating on these therapeutic categories, Taro aims to meet the evolving needs of the Canadian healthcare system and its patients.

2Sourcing Profile

Taro Pharmaceuticals Inc. primarily sources generic drug formulations from India, leveraging the country's robust pharmaceutical manufacturing capabilities. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, indicates a strategic focus on ready-to-market products that meet Canadian regulatory standards. India's established reputation for producing high-quality generics aligns with Taro's sourcing strategy, ensuring a consistent supply of affordable medications for the Canadian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Taro Pharmaceuticals Inc.,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Taro Pharmaceuticals Inc., particularly in therapeutic areas where Taro seeks to expand its product offerings. Identifying gaps in Taro's current sourcing, such as specific formulations or dosage forms not currently imported, presents potential avenues for partnership. New suppliers can enhance Taro's product portfolio and contribute to meeting the diverse needs of the Canadian market.

2Requirements & Qualifications

Indian exporters aiming to supply Taro Pharmaceuticals Inc. must ensure their manufacturing facilities are certified by recognized GMP authorities, such as EU GMP, WHO GMP, or PIC/S. Compliance with Health Canada's import licensing requirements, including obtaining a valid establishment license, is mandatory. Products must undergo batch testing, stability studies, and meet labeling requirements in both English and French. Additionally, adherence to serialization mandates is essential to ensure product traceability and security within the Canadian market.

3How to Approach

Frequently Asked Questions — Taro Pharmaceuticals Inc.,

What products does Taro Pharmaceuticals Inc., import from India?

Taro Pharmaceuticals Inc., imports 12 pharmaceutical products across 6 categories. Top imports: Temozolomide ($1.3M), Sunitinib ($900.0K), Budesonide ($700.0K), Dasatinib ($600.0K), Doxorubicin ($600.0K).

Who supplies pharmaceuticals to Taro Pharmaceuticals Inc., from India?

Taro Pharmaceuticals Inc., sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $7.3M).

What is Taro Pharmaceuticals Inc.,'s total pharmaceutical import value?

Taro Pharmaceuticals Inc.,'s total pharmaceutical import value from India is $6.8M, based on 137 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Taro Pharmaceuticals Inc., focus on?

Taro Pharmaceuticals Inc., imports across 6 categories. The largest: Advanced Oncology (63.9%), Respiratory (10.3%), Oncology (8.9%).

Get Full Taro Pharmaceuticals Inc., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.